Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6518971 | 0.84 | BCL9 (0.36) | PROKR1ALDH1A1LMNATDP1RAB9A | |
| SCHEMBL3435942 | 0.83 | ALDH1A1 (0.35) | PROKR1ALDH1A1LMNATDP1RAB9A | |
| SCHEMBL6519249 | 0.73 | PDE4B (0.42) | ALDH1A1LMNAMAPT | |
| SCHEMBL4099888 | 0.72 | RAB9A (0.57) | PROKR1ALDH1A1LMNARAB9AGAA | |
| SCHEMBL187297 | 0.70 | ALDH1A1 (0.49) | PROKR1ALDH1A1LMNARAB9AMAPT | |
| SCHEMBL6521846 | 0.69 | NOTUM (0.46) | ALDH1A1MAPT | |
| SCHEMBL16322554 | 0.67 | PARP1 (0.69) | — | |
| SCHEMBL3660445 | 0.67 | PARP1 (0.69) | — | |
| SCHEMBL2937126 | 0.66 | RAB9A (0.67) | PROKR1ALDH1A1RAB9AGAAMAPT | |
| SCHEMBL2937123 | 0.66 | RAB9A (0.67) | PROKR1ALDH1A1RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
| EP-2265611-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009112832-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PROKR1 3574/4885ALDH1A1 305/4885LMNA 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.